Relistor (methylnaltrexone) Disease Interactions
There are 3 disease interactions with Relistor (methylnaltrexone):
Peripheral opioid receptor antagonists (Includes Relistor) ↔ intestinal obstruction
Severe Potential Hazard, Moderate plausibility. Applies to: Gastrointestinal Obstruction, Diverticulitis, Peptic Ulcer, Inflammatory Bowel Disease
Peripheral opioid receptor antagonists are contraindicated in patients with known or suspected gastrointestinal obstruction, and in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation. Cases of gastrointestinal perforation have been reported in patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structure integrity in the wall of the GI tract such as peptic ulcer, diverticular disease, Crohn's disease, infiltrative GI tract malignancies or peritoneal metastases. It is recommended to monitor for the development of severe, persistent, or worsening abdominal pain and to discontinue treatment in patients who develop symptoms. The overall risk- benefit profile should be carefully evaluated before using these agents in patients with these conditions.
Methylnaltrexone (Includes Relistor) ↔ hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease
Studies have shown a significant increase in systemic exposure of methylnaltrexone in patients with moderate and severe hepatic impairment, compared to subjects with normal hepatic function. A dosage reduction is recommended in these patients. No dose adjustment is needed in patients with mild hepatic impairment.
Peripheral opioid receptor antagonists (Includes Relistor) ↔ renal impairment
Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction
Patients with moderate, severe and end-stage renal disease have shown to exhibit markedly higher systemic exposure to peripheral opioid receptor antagonists such as methylnaltrexone and naloxegol, compared to subjects with normal renal function. A dose reduction is recommended for these patients. No dosage adjustment is needed in patients with mild renal impairment.
More about Relistor (methylnaltrexone)
- Relistor Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 39 Reviews
- Drug class: peripheral opioid receptor antagonists
- FDA Alerts (1)
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.